Injection Drug Use and HIV/AIDS
- HIV/AIDS, Injection Drug Use, and Race in the US
- Supervised Consumption Spaces
- Syringe Service Programs
- Hepatitis C and Injection Drug Use
- Persons In The US Living with Diagnosed HIV Infection Ever Classified as Stage 3 (AIDS), by Transmission Method
Page last updated June 9, 2020 by Doug McVay, Editor/Senior Policy Analyst.
31. Cases of AIDS, Cumulative Through 2007
"Through 2007, a total of 1,030,832 persons in the United States and dependent areas had been reported as having AIDS (Table 16). Three states (California, Florida, and New York) reported 43% of the cumulative AIDS cases and 36% of AIDS cases reported to CDC in 2007. In the 50 states and the District of Columbia, the rate of reported AIDS cases in 2007 was 12.4 per 100,000 population. When the U.S. dependent areas were included, the rate of reported AIDS cases ranged from zero per 100,000 (American Samoa, Guam, and the Northern Mariana Islands) to 148.1 per 100,000 (District of Columbia)."
Centers for Disease Control and Prevention, "HIV/AIDS Surveillance Report, 2007," Vol. 19. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009: p. 9.
32. Spending on HIV-Related Harm Reduction, 2007
"At approximately $160 million in 2007, the estimated total spending on HIV-related harm reduction in low and middle income countries is extremely low, and would still be insufficient even if this figure was underestimated by a factor of two or three. It amounts to about three US cents a day, or $12.80 a year, for each person who injects drugs. It is clearly inadequate when compared with indicative unit costs of providing needles and syringes (approximately $100 per person per year) and methadone (approximately $500 per person per year)."
"Three cents a day is not enough: Resourcing HIV-related Harm Reduction on a global basis," International Harm Reduction Association (London, United Kingdom: 2010), p. 39.
33. Cost of HIV Treatment
The lifetime cost of treating an HIV positive person was estimated in 1997 to be $195,188.
Holtgrave, DR, Pinkerton, SD. "Updates of Cost of Illness and Quality of Life Estimates for Use in Economic Evaluations of HIV Prevention Programs." Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, pp. 54-62 (1997).
34. Global Estimated Drug-Related Mortality, 2011
"UNODC estimates that there were between 102,000 and 247,000 drug-related deaths in 2011, corresponding to a mortality rate of between 22.3 and 54.0 deaths per million population aged 15-64. This represents between 0.54 per cent and 1.3 per cent of mortality from all causes globally among those aged 15-64.20 The extent of drug-related deaths has essentially remained unchanged globally and within regions."
UNODC, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6), p. 10.
35. Cost Effectiveness of Harm Reduction
"Prevention of HIV is also cheaper than treatment of HIV/AIDS. For example, in Asia it is estimated that the comprehensive package of HIV-related harm reduction interventions costs $39 per disability-adjusted life-year saved,14 whereas antiretroviral treatment costs approximately $2,000 per life-year saved. Such figures demonstrate that harm reduction is a low-cost, high-impact intervention."
"Three cents a day is not enough: Resourcing HIV-related Harm Reduction on a global basis," International Harm Reduction Association (London, United Kingdom: 2010), p. 12.